Skip to main content
. 2018 May;10(5):2948–2959. doi: 10.21037/jtd.2018.05.55

Table S2. Patients’ groups according to resistance to crizotinib and PFS (36 evaluable patients).

Group Definition Patients, n (%) Median PFS, months (95% CI)
Poor Progression at first assessment 6 (16.7) 1.16 (0.13–1.90)
Intermediate Progression within 12 months 17 (47.2) 7.16 (2.87–11.63)
Good Progression ≥12 months or treatment ongoing 13 (36.1) 19.51 (12.33–28.90)

PFS, progression-free survival; CI, confidence intervals.